Cambridge, Massachusetts-based Apnimed, Inc. (Nasdaq: APMD) filed for an IPO on July 10, 2026, seeking a Nasdaq listing for a company whose sole clinical asset has completed two Phase III trials and an NDA submission — a profile that makes it one of the more advanced clinical-stage biotech IPO candidates in the current market. The filing comes with a near-term regulatory binary: the company expects a PDUFA target action date in Q1 2027.
Offering terms remain preliminary. The S-1 registration statement leaves share count and price range blank, as is standard for an initial filing. The company applied for listing on the Nasdaq Global Market under the ticker APMD.
Prior to the IPO filing, Apnimed had raised approximately USD 284 million through preferred equity and convertible note financings, backed by investors including Shionogi, Columbia Seligman Technology and Information Fund, and Alpha Wave Ventures. The company also secured a debt facility of up to USD 150 million from HealthCare Royalty Partners in April 2026 to support commercial readiness. Convertible notes issued in September 2025 will automatically convert into common stock at the IPO at a 10% discount to the offering price.
Strategic investor Shionogi has also supported the company through equity investments and a broader collaboration in sleep medicine. In April 2026, Apnimed sold its interest in the companies' SASS joint venture to Shionogi for USD 100 million upfront plus a potential USD 50 million development milestone, allowing it to focus on the wholly owned AD109 program while retaining royalties on future SASS products.
Apnimed's sole clinical asset AD109 (Oxnimbi) is a once-daily oral fixed-dose combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor, designed to improve upper airway muscle tone during sleep and address the neuromuscular dysfunction underlying obstructive sleep apnea. Both Phase III trials met their primary endpoints, reporting statistically significant reductions in the apnea-hypopnea index at 26 weeks. Under the on-treatment estimand, the filing states mean AHI reductions of 55.6% in SynAIRgy and 46.8% in LunAIRo versus placebo (p<0.0001 in both trials). AD109 was generally well-tolerated, with no drug-related serious adverse events reported in either trial, the filing states.